June 2026 Research Update

This month added two pieces to the same practical question: how do we detect meaningful movement change in HSP, and what kinds of training might shift everyday function. Across these studies, the clearest signal was improvement on timed or distance-based tasks and balance scores, alongside a push toward more objective, trial-ready movement measurements. Together, they point to progress in measuring and tracking mobility, even when more detailed gait lab measurements do not show obvious changes. [1] [2]

In a 3-week program combining robot-assisted gait training with traditional therapy, people with HSP walked farther on a 6-minute walk test and improved on a 10-meter walk time, balance scores, and a gross motor function measure after the program. The same study reported better perceived physical health and a suggested reduction in HSP severity scores, but formal gait analysis measurements did not significantly change. This combination suggests that some benefits may show up first in endurance, speed, and balance rather than in detailed motion patterns captured in a gait lab. [1]

A separate cross-sectional study tested a quantitative motor assessment using sensors during rapid alternating movements, comparing 41 people with HSP to matched controls. Foot tapping was the best single measure for separating HSP from controls and it also tracked with how severe symptoms were, including in mild-stage disease. Upper-limb measures appeared to shift more clearly between moderate and severe stages, which may help researchers choose the right test depending on disease stage. [2]

For patients and caregivers, these studies mainly add information about what can be measured reliably and what kinds of short-term changes have been observed in structured training. The robot-assisted training results may matter now as evidence that some people can show short-term gains in walking endurance, speed, and balance, but the study did not include a separate control group, so it cannot prove the program caused the changes. The sensor-based tapping work matters more for the future, because it supports a way to detect subtle changes (especially in milder HSP) that could make clinical trials easier to run and easier to interpret. [1] [2]

What remains uncertain is how long the improvements after robot-assisted training last, and whether they outperform other approaches when tested head-to-head. It is also not yet clear how well foot tapping as a measurement predicts day-to-day mobility over time, since this was a snapshot rather than a follow-up study. Even with those gaps, this month helped clarify that simple tasks like walking distance and foot tapping can capture differences that are meaningful and measurable in HSP research. [1] [2]

This month strengthened the idea that HSP classification is moving from symptom-based labels toward more precise genetic and imaging-supported subtypes. Across studies, targeted genetic testing captured a meaningful minority of suspected cases, while advanced spinal cord MRI pattern analysis showed very strong separation between two common subtypes in a small sample. The shared message is not that diagnosis is easy, but that the tools to sort HSP into clearer categories are improving. [3] [4]

In 657 Korean people with suspected HSP, pathogenic or likely pathogenic gene changes were found in 18% of patients. SPAST and ATL1 were the most commonly affected genes, and the targeted next-generation sequencing panel found more genetic diagnoses than Sanger sequencing. The study also highlighted that copy-number variants (larger missing or duplicated gene segments) contributed to SPAST findings, and many cases still did not have a clear genetic answer. [3]

A separate prospective study used spinal cord MRI data and computer-based feature extraction to distinguish SPG4 from SPG5. The best model reached an AUC of 1.00 in the test set, and one key MRI-derived feature also showed a moderate correlation with a clinical severity score. This suggests spinal cord imaging patterns may contain subtype-specific information, although the test set was small and needs confirmation in broader groups. [4]

For patients, these studies mainly affect diagnosis and research enrollment rather than treatment decisions. The cohort study shows that even with a focused gene panel, many people with suspected HSP may not receive a confirmed genetic cause, which helps set expectations about what current testing can and cannot explain. The MRI modeling study is promising as a future support tool for distinguishing SPG4 from SPG5, but it is not yet established as a standard clinical test based on this single report. [3] [4]

What became clearer this month is that combining approaches may keep improving classification: gene panels can detect point changes and larger deletions/duplications, while imaging-based pattern tools may provide additional clues when genetics is uncertain or when subtypes need clearer separation. What remains uncertain is how well these results carry across different hospitals, scanners, and populations, and how often imaging adds value once genetic results are known. [3] [4]

This month included multiple case reports that broaden what HSP can look like and which gene changes may be involved, but they also underline how individualized rare findings can be. Across these reports, the main contribution was expanding the catalog of genetic variants linked to spastic paraplegia and documenting less-common medical contexts that can occur alongside HSP. The pattern is useful for awareness and diagnosis, but it does not establish frequency or direct cause-and-effect. [5] [6] [7] [8] [9]

On the genetics side, one family was reported with a new homozygous POLR1A variant and a complicated HSP-like picture without clear hypomyelination at the time described, alongside a systematic review that found 27 POLR1A variants in the literature and linked three to a hypomyelinating leukodystrophy subtype. Another pediatric case identified compound heterozygous COQ4 variants, including one variant not previously reported in complicated HSP. A Colombian family with X-linked SPG2 was reported with a novel PLP1 variant that was classified as uncertain, though computer predictions and the family phenotype were considered consistent with SPG2. [5] [6] [7]

Two other case reports focused on medical situations that may intersect with HSP care. One person with pure HSP underwent CT-guided kidney mass cryoablation with standard general anesthesia and recovered without complications in that single case. Another person with genetically confirmed SPG4 developed nonischemic dilated cardiomyopathy with reduced heart pumping function and dyssynchrony, and symptoms improved with standard heart failure therapy before later receiving a resynchronization device with a defibrillator. [8] [9]

For patients and caregivers, these reports mostly matter for diagnosis and for recognizing that HSP can overlap with other neurologic or medical findings in some individuals. The genetic case reports may help families who are still searching for an explanation, because they add new variants and emphasize the role of sequencing in unusual presentations, but a single report does not prove how likely a gene is to be the cause in other families. The anesthesia and cardiomyopathy cases may matter when similar situations arise, yet they cannot predict risk for the broader HSP population. [5] [6] [7] [8] [9]

What remains uncertain is how often these genetic variants lead to the reported features, and whether findings like heart muscle weakness are truly part of SPG4 for some people or occurred for unrelated reasons. Even with that uncertainty, these reports help clarify the range of what has been observed and can help researchers and diagnostic labs interpret unusual genetic results when they appear again. [5] [9]

This month added several laboratory studies that map HSP gene changes to specific problems inside nerve cells and support cells, building a clearer picture of shared pathways. Across studies, three recurring processes stood out: how materials move along microtubules, how mitochondria stay healthy and get transported, and how cells respond to stress such as lysosome membrane damage or immune activation. Some experiments also tested compounds in models, offering early signals that certain cell problems can be partly reversed under controlled conditions. [10] [11] [12] [13] [14]

Studies of movement along microtubules and neuron structure linked gene changes to how motor proteins and long nerve fibers behave. In an in vitro KIF1A system (SPG30-related), disrupting a specific salt bridge increased motor speed but reduced how long the motor stayed attached and how strongly it bound to microtubules in the apo state, a combination that could plausibly impair reliable cargo delivery in neurons. In a mouse model of SPAST-related disease, NU-9 treatment prevented corticospinal axon degeneration and restored mitochondria and endoplasmic reticulum integrity, suggesting early vulnerability in these neurons may be modifiable in animals. [10] [11]

Work in patient-derived SPG7 neurons pointed to mitochondria problems specifically in distal neurites, with increased fragmentation and slowed forward (anterograde) mitochondrial movement early in development. Treatment with Bz-423 in this cell model reduced abnormal mitochondrial features, improved neurite growth measures, and restored forward mitochondrial transport to control levels, without apoptotic effects at the dose used in the experiment. Because this was an in vitro system with a small number of patient lines, it is best seen as an early step that defines a targetable process rather than a proven therapy for people. [12]

Two other lab studies focused on cell stress responses that may contribute to neurodegeneration. Spg11 knockout mice showed microglial activation and lipid buildup in myeloid cells, and this increased immune reactivity did not worsen alpha-synuclein pathology or dopaminergic neuron loss in two synucleinopathy models. Separately, cell experiments identified a TFG-centered complex (LASER) that helps repair damaged lysosome membranes, and disease-associated TFG mutations disrupted this repair process by impairing recruitment of ESCRT machinery. [13] [14]

For patients, these results are mainly research that may matter later by pointing to biological targets and helping explain why certain HSP types affect long nerve pathways. The NU-9 mouse findings and the Bz-423 iPSC-neuron findings are early treatment signals in models, not evidence of benefit in people with HSP. What these studies do provide now is a clearer map of processes that could be tracked or targeted in future drug development, such as mitochondrial transport, lysosome repair, and immune cell activation in the brain. [11] [12] [13] [14] [10]

What remains uncertain is which of these cellular problems are shared across many HSP types versus specific to certain genes, and whether changing these processes in models will translate into meaningful symptom changes for patients. Even so, this month helped clarify that multiple HSP genes converge on how cells handle transport and stress, offering a more connected picture of disease biology than isolated gene-by-gene explanations. [14] [13]